asininityandbeyond @asininitybeyond

@BigBiteNow She didn’t manage coherent goodbyes to my wife or kids as we didn’t understand how little time we had with her A drug offering more time would have meant a great deal Some dont appreciate that + I truly hope they dont endure something that removes the veil on that ignorance.2/2

@BigBiteNow Same applies to PFS My MiL passed away in ‘21 from uveal melanoma - a rare cancer, with very few treatment options She endured chemo + trial drugs but to no avail Her deterioration was rapid (days), with her cognitive decline being devastatingly fast + unexpected 1/2

Back to 6103, the fact the below statement precedes the pre-clinical efficacy comparison with Enhertu, says it all really: preclinical PK = modelled deep and prolonged partial responses ➡️ observed patient PK = patient anti tumour activity Read between the lines 2/2 #AVCT

Astonishing safety comparisons with Enhertu, which did $1.4bn revenue in Q1 26. The usual mention partnering, inflection points etc. We are talking serious, scaled deals given what is in the data. “Pipeline expansion”… left field… watch this space IMO 1/2 #AVCT

@111BEN_111 @RAH00084 So CCs package being addressed now is likely well timed + will be diluted less than examples you’ve shared. She is also paid at lower end of scale relative to peers + gets no bonus. For a cash strapped co, solving this with stock is prudent IMO Appreciate the discourse tho.4/4

@111BEN_111 @RAH00084 I think the rapid delivery timeframes for new drugs that the co is demonstrating sees the above monetisation look after itself; coupled with platform tech and a growing body of clinical data. Therefore, I believe that slog + river of dilution js largely behind us. 3/4

@111BEN_111 @RAH00084 At this time theres no better CEO for #AVCT, given the knowledge + leadership in FAP, team she’s built + critical period we face It’s a lot of shares, yes. But you would need to give that sort of package to any incoming US CEO. Reward + retain is the right move here All IMO.2/2

@111BEN_111 @RAH00084 McKenna joined Prometheus in 2019, IPO happened in 21 + then further c50% dilution in 22. At one point he had >6% of the co having got 2.4m options, which was then diluted down/sold. He also had a bigger salary than CC 5 years ago + 55% bonus. So more nuanced than final value.1/2

@tom_the_bomb__ IMO low hurdles are to quickly correct this It may be the last opp for such an issuance. Do it once + do it right Keep high value ppl locked in during this crucial period. To hire a new CEO, you lose org knowledge, culture, momentum + give away more than we did yesterday.3/3

@tom_the_bomb__ Also creates a ceiling for US CFO + CMO, w US biotech expectations. So CC needed a material bump to make headroom for them. Use of Aon points for US benchmarking IMO 50k shares + 3.6m options prior to this, CC had no real skin in the game. This doesn’t reflect well on anyone.2/3

Vesting conditions - 6103 readout makes sense. 6207 candidate selection has been signposted Not sure if intended to be sequential but, if so, new IND filing between the above is curious. It would logically follow the last item if 6207 related Something left field in play? #AVCT

“Navigating finances, operations + *deals*” All crucial to #AVCT’s journey but there is growing expectation around delivery of commercial deal(s) + the co seems v aware of this Right deals at the right time AVA6103 + platform validation narrative cements TO in due course, IMO

Christina Coughlin @coughlin582

2 months ago

We are thrilled to welcome Patrick to the Board at #AVCT. His deep sector experience building companies and navigating finances, operations and deals on both sides of the Atlantic will be critical for us at this time. #LetsDoThis #HopeWithoutCompromise

2 22 215 20K 0

Venk “oversaw all worldwide commercial + technical operations as well as managing the company's P&L until the successful acquisition of Cubist by $MRK” A $9.5bn transaction in 2014 money. A huge deal A proper pharma operator who has trod the path #AVCT is about to follow, IMO

@SystemsTh1nker @tom_the_bomb__ Board support also key There’s so much org knowledge about FAP, preCISION + that interaction, that a hostile TO (already uncommon in pharma) is v unlikely in this context, IMO Acquirer needs the people onside, as much as it does the IP rights. I expect a recommended cash offer.

@PR_pharma Raffa, your agenda on the stock is pretty clear I get it. You’re all in on ADC; therefore, a promising XDC platform is a threat. Both to your specialism + employer I’ve avoided engaging but hiding behind a burner + routinely chirping a co trying to make a dent in cancer is grim

An incredible development + hugely positive that #AVCT is now willing to state it so clearly: “Two analyses both demonstrate no relationship between the level of FAP expression & degree of tumor response.” Boldness superseded only by an RNS titled “PLATFORM-VALIDATING DATA”!

@tom_the_bomb__ “we expect these data will provide validation of our pre|CISION® technology in patients, by demonstrating that both our First + Second Gen molecules can effectively treat human cancers” As confident a statement that #AVCT has ever made about its clinical drugs Very telling 2/2

@tom_the_bomb__ Seems to me that a cornerstone investment of >£4.5m is likely underwritten by the comfort that (explicitly stated or otherwise) AVA6103 is working exactly as expected These statements, new indications + more sites basically confirm that for those on the outside IMO 1/2 #AVCT